Company Encyclopedia
View More
name
BIOKIN
02615.HK
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.
1.425 T
02615.HKMarket value -Rank by Market Cap -/-

Financial Score

19/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking46/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-14.94%E
    • Profit Margin-38.29%E
    • Gross Margin97.69%A
  • Growth ScoreD
    • Revenue YoY-62.32%E
    • Net Profit YoY-122.20%E
    • Total Assets YoY74.56%A
    • Net Assets YoY66.72%A
  • Cash ScoreE
    • Cash Flow Margin-261.16%D
    • OCF YoY-62.32%E
  • Operating ScoreD
    • Turnover0.23D
  • Debt ScoreC
    • Gearing Ratio41.79%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sichuan Biokin Pharma to receive credit support from Bank of China

    Sichuan Biokin Pharma to receive credit support from Bank of China

    marketscreener·
    HK
    02615
    0.00%
    HK
    03988
    +0.22%
    SH
    601988
    +3.81%
    marketscreener·
    HK
    02615
    0.00%
    HK
    03988
    +0.22%
    SH
    601988
    +3.81%

    【New Stock Listing】BIOKIN (2615) subscription entry fee is 39,293 yuan, and 5 funds including the US-listed pharmaceutical company BMS are invested in the stock

    BIOKIN (2615) is offering shares for subscription today until November 12, planning to globally issue 8.6343 million H shares, with an entry fee of HKD 39,292.31, and is expected to be listed on November 17. This offering has introduced cornerstone investors, including Bristol-Myers Squibb (BMS), who have collectively subscribed for approximately USD 32 million. The net fundraising amount is about HKD 3.018 billion, primarily for research and development and global supply chain construction. BIOKIN focuses on the research and development of biopharmaceuticals, reporting a loss of RMB 1.12 billion in the first half of 2023

    etnet·
    HK
    02615
    0.00%
    etnet·
    HK
    02615
    0.00%